Insulin-Degrading Enzyme
From Proteopedia
Line 1: | Line 1: | ||
<StructureSection load="3tuv" size="400" color="" frame="true" spin="on" Scene= align="right" caption='Rat insulin-degrading enzyme complex with peptide (green) and ATP, [[3tuv]]' > | <StructureSection load="3tuv" size="400" color="" frame="true" spin="on" Scene= align="right" caption='Rat insulin-degrading enzyme complex with peptide (green) and ATP, [[3tuv]]' > | ||
[[Image:2g49.png|left|200px]] | [[Image:2g49.png|left|200px]] | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
[[Insulin-Degrading Enzyme]] (PDB entry [[2g49]]) is a highly conserved 2*113 kDa homodimeric zinc metalloprotease. It belongs to the M16A family of metalloproteases within the ME clan. It hydrolyses insulin and several amyloidogenic peptides like amyloid-β (Aβ). | [[Insulin-Degrading Enzyme]] (PDB entry [[2g49]]) is a highly conserved 2*113 kDa homodimeric zinc metalloprotease. It belongs to the M16A family of metalloproteases within the ME clan. It hydrolyses insulin and several amyloidogenic peptides like amyloid-β (Aβ). | ||
Line 27: | Line 8: | ||
IDE could help creating IDE-based therapies to control cerebral Aβ and blood sugar concentrations thanks to the understanding of its molecular mechanisms. | IDE could help creating IDE-based therapies to control cerebral Aβ and blood sugar concentrations thanks to the understanding of its molecular mechanisms. | ||
IDE is an unusual enzyme because of its high affinity for substrates that are widely diverse in sequence and structure. IDE prefers to degrade <6 kDa bioactive peptides such as insulin, Aβ, glucagon, atrial natriuretic peptides or transforming growth factor α. Paradoxally, even though IDE targets a broad range of substrates, it shows a remarkable capacity to selectively cleave some peptides without degrading related family members. | IDE is an unusual enzyme because of its high affinity for substrates that are widely diverse in sequence and structure. IDE prefers to degrade <6 kDa bioactive peptides such as insulin, Aβ, glucagon, atrial natriuretic peptides or transforming growth factor α. Paradoxally, even though IDE targets a broad range of substrates, it shows a remarkable capacity to selectively cleave some peptides without degrading related family members. | ||
- | |||
== How are the structure and the functions of IDE related? == | == How are the structure and the functions of IDE related? == | ||
- | |||
=== Structure general points === | === Structure general points === | ||
Line 59: | Line 38: | ||
The enclosed substrate undergoes conformational changes to form β-sheets with two discrete regions of IDE for its degradation. | The enclosed substrate undergoes conformational changes to form β-sheets with two discrete regions of IDE for its degradation. | ||
IDE-N and IDE-C have extensive interactions that bury a large surface of 11,496 Ȧ<sup>2</sup> with good shape complementarity and numerous hydrogen bonds. In the absence of interactions with factors or proteins, the substrate-free IDE-c state is stable and the catalytic chamber of IDE is mostly closed. So we can consider that IDE-c is the resting and inactive state of IDE. | IDE-N and IDE-C have extensive interactions that bury a large surface of 11,496 Ȧ<sup>2</sup> with good shape complementarity and numerous hydrogen bonds. In the absence of interactions with factors or proteins, the substrate-free IDE-c state is stable and the catalytic chamber of IDE is mostly closed. So we can consider that IDE-c is the resting and inactive state of IDE. | ||
- | + | </StructureSection> | |
+ | __NOTOC__ | ||
==3D structures of insulin-degrading enzyme== | ==3D structures of insulin-degrading enzyme== | ||
Revision as of 09:02, 20 November 2013
|
3D structures of insulin-degrading enzyme
Updated on 20-November-2013
2jg4 - hIDE (mutant) – human
3qz2 - hIDE
3p7l - rIDE – rat
Insulin-degrading enzyme complexes
3n56, 3n57 – hIDE (mutant) + B-type natriuretic peptide
2yb3 - hIDE (mutant) + inhibitor
3ofi - hIDE + ubiquitin
3h44 - hIDE (mutant) + C-C motif chemokine 3
3hgz, 2g48 - hIDE (mutant) + amylin
3e4z - hIDE (mutant) + insulin-like growth factor II
3e50 - hIDE (mutant) + Transforming growth factor α
3e4a – hIDE (mutant) + hydroxamate peptide II1
2wby, 2wc0 - hIDE (mutant) + insulin
3cww - hIDE (mutant) + Bradykinin N terminal peptide
2jbu - hIDE (mutant) + co-purified peptide
2g47, 2wk3 - hIDE (mutant) + amyloid β A4
2g49 - hIDE (mutant) + glucagons
2g54 - hIDE (mutant) + insulin β chain + Zn
2g56 - hIDE + insulin β chain residues 25-54
2ypu, 4dtt, 4dwk – hIDE + inhibitor
3p7o - rIDE (mutant) + peptide
4iof – hIDE + antibody
3tuv - rIDE + peptide + ATP
</StructureSection>
References
- Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5. PMID:17613531 doi:10.1074/jbc.M701590200
- Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221 doi:10.1038/nature05143
- Li P, Kuo WL, Yousef M, Rosner MR, Tang WJ. The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition. Biochem Biophys Res Commun. 2006 May 19;343(4):1032-7. Epub 2006 Mar 22. PMID:16574064 doi:10.1016/j.bbrc.2006.03.083
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, Élodie Weider, Karsten Theis, Joel L. Sussman, Jaime Prilusky